Macquarie Reaffirms “Outperform” Rating for Addus HomeCare (NASDAQ:ADUS)

Macquarie reaffirmed their outperform rating on shares of Addus HomeCare (NASDAQ:ADUSFree Report) in a research report sent to investors on Monday morning,Benzinga reports. The brokerage currently has a $139.00 target price on the stock.

Several other equities analysts have also issued reports on ADUS. Stephens reaffirmed an “overweight” rating and issued a $138.00 price target on shares of Addus HomeCare in a research report on Tuesday, August 6th. Oppenheimer lifted their target price on shares of Addus HomeCare from $140.00 to $145.00 and gave the stock an “outperform” rating in a report on Monday, September 23rd. Royal Bank of Canada reiterated an “outperform” rating and issued a $141.00 target price on shares of Addus HomeCare in a research note on Tuesday, September 3rd. TD Cowen raised their price target on shares of Addus HomeCare from $128.00 to $137.00 and gave the company a “buy” rating in a research report on Thursday, August 8th. Finally, StockNews.com cut Addus HomeCare from a “strong-buy” rating to a “buy” rating in a research report on Sunday, July 7th. One equities research analyst has rated the stock with a sell rating, eight have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $131.63.

View Our Latest Stock Analysis on Addus HomeCare

Addus HomeCare Price Performance

NASDAQ:ADUS opened at $129.08 on Monday. The firm has a market capitalization of $2.34 billion, a P/E ratio of 29.54, a PEG ratio of 2.33 and a beta of 1.04. Addus HomeCare has a one year low of $81.51 and a one year high of $136.12. The company’s 50-day simple moving average is $129.71 and its 200 day simple moving average is $120.97.

Addus HomeCare (NASDAQ:ADUSGet Free Report) last posted its quarterly earnings results on Monday, November 4th. The company reported $1.30 earnings per share for the quarter, topping the consensus estimate of $1.28 by $0.02. The company had revenue of $289.80 million for the quarter, compared to the consensus estimate of $289.42 million. Addus HomeCare had a return on equity of 10.12% and a net margin of 6.50%. The firm’s quarterly revenue was up 7.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.03 EPS. On average, equities research analysts expect that Addus HomeCare will post 4.57 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Esteban Lopez sold 500 shares of Addus HomeCare stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $127.50, for a total value of $63,750.00. Following the completion of the sale, the director now owns 3,366 shares of the company’s stock, valued at $429,165. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other Addus HomeCare news, EVP Michael D. Wattenbarger sold 21,917 shares of the company’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $133.29, for a total transaction of $2,921,316.93. Following the completion of the sale, the executive vice president now directly owns 7,215 shares of the company’s stock, valued at approximately $961,687.35. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Esteban Lopez sold 500 shares of the stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $127.50, for a total transaction of $63,750.00. Following the completion of the transaction, the director now owns 3,366 shares in the company, valued at $429,165. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 22,917 shares of company stock valued at $3,050,082 in the last ninety days. 4.60% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Addus HomeCare

A number of hedge funds have recently modified their holdings of ADUS. UMB Bank n.a. lifted its position in Addus HomeCare by 64.2% during the second quarter. UMB Bank n.a. now owns 225 shares of the company’s stock valued at $26,000 after purchasing an additional 88 shares in the last quarter. Quest Partners LLC purchased a new stake in Addus HomeCare in the second quarter worth about $31,000. EntryPoint Capital LLC bought a new position in shares of Addus HomeCare in the first quarter worth about $44,000. Innealta Capital LLC purchased a new position in shares of Addus HomeCare during the 2nd quarter valued at about $44,000. Finally, Farther Finance Advisors LLC lifted its position in shares of Addus HomeCare by 9,150.0% during the 3rd quarter. Farther Finance Advisors LLC now owns 370 shares of the company’s stock valued at $49,000 after buying an additional 366 shares in the last quarter. Institutional investors own 95.35% of the company’s stock.

About Addus HomeCare

(Get Free Report)

Addus HomeCare Corporation, together with its subsidiaries, provides personal care services to elderly, chronically ill, disabled persons, and individuals who are at risk of hospitalization or institutionalization in the United States. The company operates through three segments: Personal Care, Hospice, and Home Health.

See Also

Analyst Recommendations for Addus HomeCare (NASDAQ:ADUS)

Receive News & Ratings for Addus HomeCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Addus HomeCare and related companies with MarketBeat.com's FREE daily email newsletter.